[go: up one dir, main page]

MX2020013785A - Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. - Google Patents

Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.

Info

Publication number
MX2020013785A
MX2020013785A MX2020013785A MX2020013785A MX2020013785A MX 2020013785 A MX2020013785 A MX 2020013785A MX 2020013785 A MX2020013785 A MX 2020013785A MX 2020013785 A MX2020013785 A MX 2020013785A MX 2020013785 A MX2020013785 A MX 2020013785A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
medical use
derivative
pyridopyrimidine derivative
Prior art date
Application number
MX2020013785A
Other languages
English (en)
Inventor
Feng He
Weikang Tao
Guobao Zhang
Yiqian Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020013785A publication Critical patent/MX2020013785A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un derivado de la pirido-pirimidina, como se muestra en la fórmula general (I), un método de preparación del mismo y una composición farmacéutica que contiene el derivado y el uso del mismo como agente terapéutico, particularmente como un agonista de TLR8; en donde cada sustituyente de fórmula general (I) es el mismo que los definidos en la descripción. (ver Fórmula).
MX2020013785A 2018-07-03 2019-07-02 Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. MX2020013785A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810717585 2018-07-03
CN201811317059 2018-11-07
PCT/CN2019/094310 WO2020007275A1 (zh) 2018-07-03 2019-07-02 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2020013785A true MX2020013785A (es) 2021-03-25

Family

ID=69059273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013785A MX2020013785A (es) 2018-07-03 2019-07-02 Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.

Country Status (12)

Country Link
US (1) US12162879B2 (es)
EP (1) EP3822271A4 (es)
JP (1) JP7349456B2 (es)
KR (1) KR20210028208A (es)
CN (2) CN115710266B (es)
AU (1) AU2019299609B9 (es)
BR (1) BR112020026890A2 (es)
CA (1) CA3105286A1 (es)
MX (1) MX2020013785A (es)
TW (1) TWI823959B (es)
UA (1) UA128528C2 (es)
WO (1) WO2020007275A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115710266B (zh) * 2018-07-03 2024-09-13 江苏恒瑞医药股份有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN114222742B (zh) * 2019-08-19 2024-07-23 上海挚盟医药科技有限公司 一类2-氨基嘧啶类化合物及其药物组合物和用途
KR20220123437A (ko) * 2020-01-02 2022-09-06 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 피리도피리미딘 유도체의 결정형 및 이의 제조 방법
CN116981446A (zh) * 2021-03-03 2023-10-31 苏州盛迪亚生物医药有限公司 一种包含吡啶并嘧啶类衍生物的药物组合物及其制备方法
WO2023020347A1 (zh) * 2021-08-16 2023-02-23 华润医药研究院（深圳）有限公司 嘧啶并吡啶类化合物及其制备方法和医药用途
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
US20250059183A1 (en) * 2021-12-08 2025-02-20 Shanghai Visonpharma Co., Ltd. Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist
US20250163051A1 (en) * 2022-02-24 2025-05-22 Sunshine Lake Pharma Co., Ltd. Pyrimido aromatic ring compound and use thereof in drug
CN119604504A (zh) * 2022-09-16 2025-03-11 四川科伦博泰生物医药股份有限公司 一类双并环化合物、其制备方法及用途
TW202430183A (zh) * 2022-12-16 2024-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｔｏｌｌ樣受體調節劑與ｄｓＲＮＡ的聯合治療
WO2024199000A1 (zh) * 2023-03-27 2024-10-03 西安新通药物研究股份有限公司 炔基取代的吡啶并[3,2-d]嘧啶衍生物及其作为tlr8激动剂的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026052A1 (en) 2000-09-26 2002-04-04 Unilever N.V. Composition comprising a fat phase, vegetable matter and salt
WO2005009967A2 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
CN101115479A (zh) * 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
AR059037A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
HRP20150892T1 (hr) 2008-03-03 2015-09-25 Novartis Ag Spojevi i sastavi kao modulatori tlr-aktivnosti
BRPI0907297A2 (pt) 2008-04-16 2016-08-23 Angus Chemical processo para a nitração seletiva de hidrocarbonetos, processo para preparar um nitroálcool, um aminoálcool, uma oxazolidina,uma n-alquilidroxilamina e um composto, composto, uso de um aminoálcool, uma oxazolidina, uma hidroxilamina e uso de composto.
WO2010054279A1 (en) 2008-11-10 2010-05-14 Schering Corporation Compounds for the treatment of inflammatory disorders
KR20120055623A (ko) 2009-08-07 2012-05-31 글락소스미스클라인 바이오로지칼즈 에스.에이. 지질화된 옥소아데닌 유도체
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
FR2959510B1 (fr) * 2010-04-28 2013-04-26 Centre Nat Rech Scient Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques
JP2013525431A (ja) 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
EA028254B1 (ru) 2011-05-18 2017-10-31 Янссен Сайенсиз Айрлэнд Юси Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
WO2013033345A1 (en) 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
EP3722297A1 (en) 2015-03-04 2020-10-14 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
JP6893501B2 (ja) 2015-09-17 2021-06-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
CN115710266B (zh) * 2018-07-03 2024-09-13 江苏恒瑞医药股份有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN111094289B (zh) 2022-11-22
UA128528C2 (uk) 2024-08-07
TWI823959B (zh) 2023-12-01
US12162879B2 (en) 2024-12-10
EP3822271A1 (en) 2021-05-19
WO2020007275A1 (zh) 2020-01-09
AU2019299609B9 (en) 2024-07-11
JP7349456B2 (ja) 2023-09-22
JP2021529190A (ja) 2021-10-28
US20210269439A1 (en) 2021-09-02
AU2019299609A1 (en) 2021-01-07
EP3822271A4 (en) 2022-04-13
KR20210028208A (ko) 2021-03-11
TW202019925A (zh) 2020-06-01
CN115710266A (zh) 2023-02-24
AU2019299609B2 (en) 2024-06-27
CN111094289A (zh) 2020-05-01
CN115710266B (zh) 2024-09-13
CA3105286A1 (en) 2020-01-09
BR112020026890A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
PH12020551305A1 (en) Pharmaceutical Compounds
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TN2022000039A1 (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX391655B (es) Derivado de oxopicolinamida, metodo de preparacion y uso farmaceutico del mismo
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
SA519401336B1 (ar) تركيبة صيدلية
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
GEAP201914678A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MY206745A (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
MX2020011818A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections